Platelet glycoprotein IIb/IIIa antagonists: Perioperative implications

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 2, 2001, Pages 237-240

  Sreeram, Gautam M ^a   Sharma, Ajeet D ^a   Slaughter, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cardiac surgery; Platelet antagonists; Platelet glycoproteins; Platelets

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; CARDIOPULMONARY BYPASS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA;

EID: 0035075336     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.21991     Document Type: Article

References (34)

1. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months
2. Platelet GP IIb/IIIa blockers
3. Related binding mechanisms for fibrinogen, fibronectin, von Willebrands factor, and thrombospondin on thrombin-stimulated human platelets
4. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
5. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
6. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa receptor
7. Immediate and reversible platelet inhibition following intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention: Results of a dose finding study
8. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
9. Disposition of 14C-eptifibatide after intravenous administration to healthy men
10. Safe use of platelet GP IIb/IIIa inhibitors
11. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
12. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb-IIIa blockade
13. Authors' reply
14. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II
15. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
16. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
17. Platelet glycoprotein IIb/IIIa blockade with abciximab with low-dose heparin during percutaneous coronary revascularization
18. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
19. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
20. Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary artery bypass surgery
21. For the IMPACT-II Investigators: Bleeding with coronary artery bypass surgery (CABG) in patients treated with a platelet glycoprotein IIb/IIIa inhibitor
22. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
23. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT
24. Glycoprotein IIb/IIIa integrin blockade
25. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
26. Routine platelet transfusions in patients undergoing emergency coronary artery bypass surgery alter receiving abciximab
27. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary artery bypass graft surgery
28. Treatment with a GP IIb/IIIa antagonist inhibits thrombin generation in platelet rich plasma from patients
29. Emergency coronary artery bypass graft surgery in abciximab-treated patients
30. Surgical implications of platelet glycoprotein IIb-IIIa inhibition
31. Immunomodulatory aspects of transfusion
32. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: Increased costs and platelet transfusion requirements after the use of abciximab
33. The effects of aprotinin on platelets in vitro using whole blood flow cytometry
34. Reopro removal during cardiopulmonary bypass using a hemoconcentrator